Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Inclusion Criteria:

Patients must be/have:

• Histological evidence of malignancy
• Advanced solid tumors that have recurred or progressed following standard therapy
• Failed one prior therapy or have no standard therapy available
• Ambulatory with ECOG of 0-1 and estimated life expectancy of > 3 months
• If female, negative pregnancy test
• If of childbearing years, agree to use birth control
• If patient with prior radiation therapy for brain metastases, on steroids, must have been stable for 1 month

Exclusion Criteria:

Patients will be excluded if they are or have had:

• Prior radiation within 4 weeks
• Active medical condition or organ disease which may compromise safety or interfere with the study
• Clinically significant cardiac co-morbidities or pulmonary impairment
• Concomitant therapy needs
• Treated with any investigational drugs within 30 days
• Tumors involve major artery or vein
• Prior or concurrent central nervous system (CNS) disease
• Less than 4 weeks since major surgery
• Known to be positive for HIV, hepatitis B or C
• Concurrent use of aspirin
• Use of thrombolytic agents
• Uncontrolled hypertension
• Grade II-IV peripheral vascular disease
• Pregnant or lactating
• Prior allergic history to compounds of similar chemical composition
• Inpatients
• Grade II-IV peripheral neuropathy